Bicyclic heterocycl yl derivatives as IRAK4 inhibitors

MYPI2025001601A0Undetermined Publication Date: 2015-07-13AURIGENE ONCOLOGY LIMITED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025001601
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2014-06-20
Filing Date
2015-01-12
Publication Date
2015-07-13
Patent Text Reader

Abstract

(FORMULA 1) The present invention provides bicyclic heterocyclyl kinase enzyme inhibitor compounds of formula (1), which are therapeutically useful as kinase inhibitors, particularly IRAK4 inhibitors, wherein A, Y, Z, X₁, X₂, X₃, R₁, R₃, ‘m’, ‘n’ and ‘p’ have the meanings given in the specification and pharmaceutically acceptable salt or stereolsomer thereof that are useful in the treatment and prevention of diseases or disorder, in particular their use in diseases or disorder mediated by kinase enzyme, particularly IRAK4 enzyme. The present invention also provides pharmaceutical composition comprising at least one of the compounds of compound of formula (I) together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
Need to check novelty before this filing date? Find Prior Art